Changes

==Cancer Category/Type==

==Cancer Category/Type==

Universal tumor suppressor associated with many cancer types

Universal tumor suppressor associated with many cancer types.

==Gene Overview==

==Gene Overview==

The ''TP53'' gene is well-known tumor suppressor gene that has been implicated in many cancer types.  (Wang, et al. 2018) The ''TP53'' protein product is involved in regulating the cell cycle pathway and can prevent replication if cell damage has occurred. (Hampp, et al. 2016)  Deletions, LOH, and loss of function (LOF) mutations have been associated with ''TP53''.  These alterations often confer a poor prognosis [CITE] and chemoresistance [CITE].   

The ''TP53'' gene is well-known tumor suppressor gene that has been implicated in many cancer types.  (Wang, et al. 2018) The ''TP53'' protein product is involved in regulating the cell cycle pathway and can prevent replication if cell damage has occurred. (Hampp, et al. 2016)  Deletions, LOH, and loss of function (LOF) mutations have been associated with ''TP53''.  These alterations often confer a poor prognosis [CITE] and chemoresistance [CITE].   

==Most common types of alterations observed in TP53==

==Most common types of alterations observed in TP53==

'''[https://www.ncbi.nlm.nih.gov/books/NBK1311/ GeneReviews]''' - information on Li Fraumeni Syndrome

'''[https://www.ncbi.nlm.nih.gov/books/NBK1311/ GeneReviews]''' - information on Li Fraumeni Syndrome

==Cited Refereces==

==References=

1. Hampp S, et al. DNA damage tolerance pathway involving DNA polymerase ι and the tumor suppressor p53 regulates DNA replication fork progression. PNAS 2016 Jul 26; 113(30): E4311-9. doi: 10.1073/pnas.1605828113.

1. Hampp S, et al., (2016). DNA damage tolerance pathway involving DNA polymerase ι and the tumor suppressor p53 regulates DNA replication fork progression. PNAS 113(30): E4311-4319, PMID: 27407148.  

2. Wang M, et al. Characterizing genomic differences of human cancer stratified by the TP53 mutation status. Mol Genet Genomics. 2018 Jan 12. doi: 10.1007/s00438-018-1416-7. [Epub ahead of print]

2. Wang M, et al., (2018). Characterizing genomic differences of human cancer stratified by the TP53 mutation status. Mol Genet Genomics doi: 10.1007/s00438-018-1416-7 [Epub ahead of print], PMID 29330617.

== Notes ==

== Notes ==

<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.